Advertisements


We are Sorry, This Page doesn't Exist


Vertex"s Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids

Vertex (VRTX) gains an EU approval for Orkamb.....»»

Category: dealsSource: nytJan 22nd, 2019

Vertex"s Cystic Fibrosis Drug Gets FDA Nod for Children

Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years .....»»

Category: personnelSource: nytAug 16th, 2018

Vertex announces FDA approval of ORKAMBI to treat cystic fibrosis

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 7th, 2018

Vertex"s Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids

Zacks.....»»

Category: topSource: redinewsJan 22nd, 2019

Vertex completes enrollment of two Phase 3 studies of cystic fibrosis candidate

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 6th, 2018

Vertex Hits The Top, As Competitor Galapagos Doesn"t Impress In Cystic Fibrosis Study

Vertex Hits The Top, As Competitor Galapagos Doesn"t Impress In Cystic Fibrosis Study.....»»

Category: topSource: seekingalphaJul 2nd, 2018

Arrowhead presents new data on ARO-ENac for treatment of Cystic Fibrosis

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 21st, 2018

Vertex Hits Stumbling Block For One Triple-Combo Therapy For Cystic Fibrosis

Vertex Hits Stumbling Block For One Triple-Combo Therapy For Cystic Fibrosis.....»»

Category: topSource: seekingalphaApr 30th, 2018

Evolus Gains FDA Approval For Treatment Of Frown Lines, Set To Rival Allergan

Evolus Gains FDA Approval For Treatment Of Frown Lines, Set To Rival Allergan.....»»

Category: topSource: seekingalpha8 hr. 16 min. ago

Merck Gets Priority Review for Keytruda Combo in Kidney Cancer

Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common typ.....»»

Category: personnelSource: nyt18 hr. 1 min. ago

Conatus (CNAT) Completes Enrollment in Phase II NASH Study

Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or.....»»

Category: smallbizSource: nytFeb 13th, 2019

Novartis gets FDA approval for Egaten for the treatment of fascioliasis

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 13th, 2019

Outside the Box: Harry Boxer’s stocks to watch include maker of Botox competitor

Evolus received FDA approval for a treatment for frown lines......»»

Category: topSource: marketwatchFeb 8th, 2019

Genfit And Elafibranor In NASH Fibrosis: The FDA Guidelines For Conditional Approval

Genfit And Elafibranor In NASH Fibrosis: The FDA Guidelines For Conditional Approval.....»»

Category: topSource: seekingalphaJan 31st, 2019

Clovis" Rubraca Gets Nod as Maintenance Therapy in Europe

Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer pati.....»»

Category: personnelSource: nytJan 28th, 2019

Gilead And Selonsertib In NASH Fibrosis And Compensated Cirrhosis: The FDA Guidelines For Conditional Approval

Gilead And Selonsertib In NASH Fibrosis And Compensated Cirrhosis: The FDA Guidelines For Conditional Approval.....»»

Category: topSource: seekingalphaJan 27th, 2019

Acorda Gets FDA Approval for Parkinson"s Disease Drug Inbrija

Acorda (ACOR) gains an FDA nod for its lead Parkinson's drug Inbrija pertaining to the treatment of OFF periods in patients afflicted .....»»

Category: smallbizSource: nytDec 24th, 2018

AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib

AbbVie (ABBV) submits regulatory applications in the United States and EU for upadacitinib, for the treatment of a.....»»

Category: personnelSource: nytDec 21st, 2018

Nabriva files 2 NDAs seeking approval for experimental pneumonia treatment

Nabriva Therapeutics on Thursday submitted two new drug applications with the Food and Drug Administration seeking marketing approval for intravenous and oral formulation of Lefamulin to treat community-acquired bacterial pneumonia in adults. “The .....»»

Category: topSource: bizjournalsDec 20th, 2018

Merck"s Keytruda Gets FDA Approval for Rare Skin Cancer

Merck (MRK) wins an accelerated approval from the FDA to expand Keytruda's label for the treatment of adult and pediatric patients with r.....»»

Category: smallbizSource: nytDec 20th, 2018